Efficacy of 5-FU/LV plus CPT-11 as first-line adjuvant chemotherapy for stage IIIa colorectal cancer

Oncology Reports

Volumn 22, Issue 3, 2009, Pages 621-629

  Mukai, Masaya ^a   Okada, Kazutake ^a   Fukumitsu, Hiroshi ^a   Yazawa, Naoki ^a   Hoshikawa, Tatsuhiko ^a   Tajima, Takayuki ^a   Hirakawa, Hitoshi ^a   Ogoshi, Kyouji ^b   Makuuchi, Hiroyasu ^a  

^a TOKAI UNIVERSITY HACHIOJI HOSPITAL   (Japan)

^b TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

5 FU LV; Adjuvant chemotherapy; Colorectal cancer; CPT 11; Occult neoplastic cells; PSK; UFT

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; KRESTIN; UFT; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE;

AGED; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURGERY; COLORECTAL CANCER; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SURVIVAL RATE; VOMITING; ADJUVANT CHEMOTHERAPY; COLORECTAL TUMOR; MORTALITY; PATHOLOGY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; FLUOROURACIL; HUMANS; LEUCOVORIN; NEOPLASM STAGING;

EID: 70349306751     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000481     Document Type: Article

References (30)

1. Multi-Institutional Registry of Large Bowel Cancer in Japan, vol. 23, Cases treated in 1994. Japanese Society for Cancer of the Colon and Rectum, Tokyo, 2002.
2. Makuuchi M and Sugihara K: Knacks & Pitfalls: Surgery of the Colon, Rectum and Anus (2nd edition). Bunkoudou Co., Ltd., Tokyo, 2004.
3. Guideline for Large Bowel Cancer in Japan. Japanese Society for Cancer of the Colon and Rectum, Tokyo, 2005.
4. TNM classification of malignant tumours (6th edition), John Wiley & Sons, Inc., New York, 2002.
5. General Rules for Clinical and Pathological Studies on Cancer of the Colon, Rectum and Anus. Japanese Society for Cancer of the Colon and Rectum (7th Edition). Kanehara & Co., Ltd., Tokyo, 2006.
6. National Institutes of Health Consensus Development Panel. National Institutes of Health consensus development conference statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst 93: 979-989, 2001.
7. Goldhirsch A, Glick JH, Gelber RD, Coates AS and Senn HJ: Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Clin Oncol 19: 3817-3827, 2001.
8. Abrams JS: Adjuvant therapy for breast cancer-results from the USA consensus conference. Breast Cancer 8: 298-304, 2001.
9. Mukai M: Occult neoplastic cells and malignant micro-aggregates in lymph node sinuses: review and hypothesis. Oncol Rep 14: 173-175, 2005.
10. Mukai M, Sato S, Tajima T, Kimura T, Komatsu N, Ninomiya H, Nakasaki H, Ogoshi K and Makuuchi H: Predicting recurrence and metastasis of stage III/Dukes' C colorectal cancer with lymph node metastasis. Oncol Rep 12: 1301-1304, 2004.
11. Mukai M, Sato S, Ninomiya H, Wakui K, Tsuchiya K, Komatsu N, Nakasaki H and Makuuchi M: Recurrence and 5-FU sensitivity of stage III/Dukes' C colorectal cancer with occult neoplastic cells in lymph node sinuses. Oncol Rep 14: 1165-1169, 2005.
12. Mukai M, Sato S, Ninomiya H, Wakui K, Komatsu N, Matsui N, Nakamura M, Nakasaki H and Makuuchi H: Sensitivity to CPT-11 and platinum derivatives for stage III/Dukes' C colorectal cancer with occult neoplastic cells in lymph node sinuses. Oncol Rep 17: 1027-1032, 2007.
13. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandic P, Iveson T, Carmichael J, Alaki M, Gruia G, Awad L and Rougier P: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomized trial. Lancet 355: 1041-1047, 2000.
14. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL and Miller L, for the Irinotecan study group: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 343: 905-914, 2000.
15. Tournigand C, Achille TAE, Lledo G, Flesh M, Quinaux DM-ME, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C and De Gramont A: FOLFIRI followed by FOLFOX 6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22: 229-237, 2004.
16. Colucci G, Gebbia V, Paoletti G, Giuliani F, Caruso M, Gebbia N, Cartení G, Agostara B, Pezzella G, Manzione L, Borsellino N, Misino A, Romito S, Durini E, Cordio S, Seri MD, Lopez M and Maiello E: Phase III randomized trial of FOLFIRI versus FOLFOX 4 in the treatment of advanced colorectal cancer: a multicenter study of Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 23: 4866-4875, 2005.
17. Machover D, Schwarzenberg L, Goldschmidt E, Tourani JM, Michalski B, Hayat M, Dorval T, Misset JL, Jasmin C, Maral R and Mathe G: Treatment of advanced colorectal and gastric adenocarcinomas with 5-FU combined with high-dose folinic acid: a pilot study. Cancer Treat Rep 66: 1803-1807, 1982.
18. Ito I, Mukai M, Ninomiya H, Kishima K, Tsuchiya K, Tajima T, Oida Y, Nakamura M and Makuuchi H: Comparison between intravenous and oral postoperative adjuvant immunochemotherapy in patients with stage II colorectal cancer. Oncol Rep 20: 1189-1194, 2008.
19. Ito I, Mukai M, Ninomiya H, Kishima K, Tsuchiya K, Tajima T, Oida Y, Nakamura M and Makuuchi H: Comparison between intravenous and oral postoperative adjuvant immunochemotherapy in patients with stage III colorectal cancer. Oncol Rep 20: 1521-1526, 2008.
20. Mukai M, Kishima K, Uchiumi F, Ishibashi E, Tajima T, Fukasawa M, Nakamura M and Makuuchi M: Comparison of QOL and adverse events for postoperative adjuvant chemotherapy in outpatients with node-positive colorectal cancer or gastric cancer. Oncol Rep 21: 1061-1066, 2009.
21. Wolmark N, Rockette H, Fisher B, Wickerham DL, Redmond C, Fisher ER, Jones J, Mamounas EP, Ore L, Petrelli NJ, Spurr CL, Dimitrov N, Romond EH, Sutherland CM, Kardinal CG, DeFusco PA and Jochimsen P: The benefit of leukovorin-modurated fluorouracil as post operative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-03. J Clin Oncol 11: 1879-1887, 1993.
22. Duschinsky R, Pleven E and Heidelberger C: The synthesis of 5-fluoropyrimidines. J Am Chem Soc 79: 4559-4560, 1957.
23. Heidelberger C, Leibman KC, Harbers E and Bhargava PM: The comparative utilization of uracil-2-c14 by liver, intestinal mucosa and Flexner-jobling carcinoma in the rat. Cancer Res 17: 399-404, 1957.
24. Berger SH and Hakala MT: Relationship of dUMP and free FdUMP pools to inhibition of thymidylate synthase by 5-fluorouracil. Mol Pharmacol 25: 303-309, 1984.
25. Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA and Fryer JG: A prospective randomized comparison of continuous infusion of fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a mid-Atlantic Oncology Program study. J Clin Oncol 17: 425-432, 1989.
26. De Gramont A, Bosset JF, Milan C, Rougier P, Bouché O, Etienne PL, Morvan F, Louvet C, Guillot T, François E and Bedenne L: Randomized trial comparing monthly low dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer. J Clin Oncol 15: 808-815, 1997.
27. Feinstein AR, Sosin DM and Wells CK: The Will Rogers phenomenon: stage migration and new techniques as a source of misleading statistics for survival in cancer. N Engl J Med 312: 1604-1608, 1985.
28. Bunt AMG, Hermans J, Smit VTHBM, van de Velde CJH, Fleuren GL and Bruijn JA: Surgical/pathologic stage migration confounds comparisons of gastric cancer survival rates between Japan and Western countries. J Clin Oncol 13: 19-25, 1995.
29. Scheithauer W, Rosen H, Kornek GV, Sebesta C and Depisch D: Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with matastatic colorectal cancer. Br Med J 306: 752-755, 1993.
30. Takahashi Y and Nishioka K: Survival without tumor shrinkage: re-evaluation of survival gain by cytostatic effect of chemotherapy. J Natl Cancer Inst 87: 1262-1263, 1995.